Faeth Therapeutics (4070) Price & Analysis

1 Followers

4070 Stock Chart & Stats

€28.40

€0.00(0.00%)

At close: Jul 27 4:00 PM EDT

€28.40

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€6.00 - €34.60

Previous CloseN/A

Volume0.00

Average Volume (3M)48.00

Market Cap

€870.22M

Enterprise Value-€38.00

Total Cash (Recent Filing)€186.44M

Total Debt (Recent Filing)€592.00K

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Nov 10, 2026

EPS Estimate

-0.68

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-141.65

Shares Outstanding25,840,425

10 Day Avg. Volume124

30 Day Avg. Volume48

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)0.72

Price to Sales (P/S)0.00

P/FCF Ratio-0.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€48.24

Price Target Upside69.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-12.88

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageMinimal debt reduces solvency and interest-burden risk while preserving flexibility to fund the development pipeline. Although the company is not yet profitable, a low-leverage balance sheet provides more room to manage losses and pursue financing or investment decisions over the coming quarters.

Improving Free Cash FlowThe smaller latest TTM cash outflow suggests some progress in controlling or absorbing development spending, even though cash flow remains negative. If sustained, this improvement could extend financial runway and reduce the pace of external funding required while the pipeline advances.

Performance-linked IncentivesStrict performance-based vesting links employee and leadership rewards to a demanding long-term outcome rather than routine service alone. This can improve alignment around shareholder value creation and strategic execution, although it does not by itself improve current revenue or cash generation.

Bears Say

No Revenue TractionThe absence of meaningful revenue indicates that Faeth remains a development-stage biotechnology business without a self-sustaining commercial engine. Continued large losses leave future financial progress dependent on successful pipeline development, commercialization, or additional capital rather than established customer demand.

Persistent Cash BurnOngoing operating and free cash outflows mean the business currently consumes capital instead of funding itself. Even with recent improvement, persistent burn can constrain research and development choices, increase dependence on financing, and make durable earnings contingent on future pipeline success.

Potential Shareholder DilutionThe financing program gives Faeth access to capital for ongoing needs but creates a structural dilution risk if shares are sold. The large preferred-stock conversion has already expanded the common share base, potentially reducing existing holders’ ownership percentage as funding needs continue.

Faeth Therapeutics News

Faeth Therapeutics initiated with a Buy at TD Cowen

TD Cowen analyst Tara Bancroft initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and no price...

1d ago

FTH

Faeth Therapeutics announces inducement grants under Nasdaq listing rule

Faeth Therapeutics (FTH) announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options...

13d ago

FTH

Faeth Therapeutics initiated with a Buy at Needham

Needham analyst Gil Blum initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $56 price target...

20d ago

FTH

Faeth Therapeutics granted Fast Track desingation for PIKTOR plus Paclitaxel

Faeth Therapeutics (FTH) announced that the U.S. Food and Drug Administration has granted Fast Track designation to the...

24d ago

FTH

Faeth Therapeutics appoints Tiwari, Biegler as Senior Vice Presidents

Faeth Therapeutics (FTH) announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler...

25d ago

FTH

Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target

Gil Blum, an analyst from Needham, has initiated a new Buy rating on Faeth Therapeutics (FTH). Gil Blum...

20d ago

FTH

Analyst Reiterates Buy on Faeth, Maintains $60 Price Target Ahead of Phase 2 Readouts

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Faeth Therapeutics. The associated price target...

1M ago

FTH

BTIG Reiterates Buy on PIKTOR as New PK/PD Data De-Risk Development and Support Unchanged $55 Price Target

Analyst Jeet Mukherjee from BTIG maintained a Buy rating on Faeth Therapeutics and keeping the price target at...

1M ago

FTH

Faeth Therapeutics: Buy Rating Reiterated as PIKTOR Advances in Key Oncology Trials; $60 Price Target Maintained

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Faeth Therapeutics, retaining the price target of...

1M ago

FTH

Faeth Therapeutics management to meet with BTIG

Meeting to be held in Baltimore/Washington, DC on August 10 hosted by BTIG. Published first on TheFly –...

1M ago

FTH

Faeth Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Boris Peaker initiated coverage of Faeth Therapeutics (FTH) with a Buy rating and $55 price target...

1M ago

FTH

Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year

“Our combination with Sensei Biotherapeutics marked an important milestone in the history of Faeth Therapeutics (FTH),” said Anand...

1M ago

FTH

Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

BSX

Faeth Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Faeth Therapeutics (FTH) with an Outperform rating and $56 price target The firm’s...

1M ago

FTH

4070 FAQ

What was Faeth Therapeutics’s price range in the past 12 months?

Faeth Therapeutics lowest stock price was €6.00 and its highest was €34.60 in the past 12 months.

What is Faeth Therapeutics’s market cap?

Faeth Therapeutics’s market cap is €870.22M.

When is Faeth Therapeutics’s upcoming earnings report date?

Faeth Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 61 days.

How were Faeth Therapeutics’s earnings last quarter?

Faeth Therapeutics released its earnings results on Aug 04, 2026. The company reported -€2.442 earnings per share for the quarter, missing the consensus estimate of -€2.266 by -€0.175.

Is Faeth Therapeutics overvalued?

According to Wall Street analysts Faeth Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faeth Therapeutics pay dividends?

Faeth Therapeutics does not currently pay dividends.

What is Faeth Therapeutics’s EPS estimate?

Faeth Therapeutics’s EPS estimate is -0.68.

How many shares outstanding does Faeth Therapeutics have?

Faeth Therapeutics has 25,840,425 shares outstanding.

What happened to Faeth Therapeutics’s price movement after its last earnings report?

Faeth Therapeutics reported an EPS of -€2.442 in its last earnings report, missing expectations of -€2.266. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Faeth Therapeutics?

Currently, no hedge funds are holding shares in DE:4070

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Faeth Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

495.62%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Faeth Therapeutics

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Faeth Therapeutics (4070) Earnings & Revenues

Historic Earnings Reports

4070 Stock 12 Month Forecast

Average Price Target

€48.24

▲(69.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","52":"€52","16.75":"€16.75","28.5":"€28.5","40.25":"€40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51.5818434,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€51.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.23857577222221,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€48.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.84456689,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,16.75,28.5,40.25,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,30.552449492307694,32.304898984615384,34.057348476923075,35.80979796923077,37.56224746153846,39.31469695384615,41.06714644615384,42.81959593846154,44.57204543076923,46.32449492307693,48.07694441538462,49.82939390769231,{"y":51.5818434,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,30.29527505940171,31.790550118803417,33.28582517820513,34.781100237606836,36.27637529700854,37.77165035641025,39.26692541581196,40.76220047521367,42.25747553461538,43.75275059401709,45.24802565341879,46.7433007128205,{"y":48.23857577222221,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.8,29.957274376153848,31.114548752307694,32.27182312846154,33.429097504615385,34.586371880769235,35.74364625692308,36.90092063307692,38.05819500923077,39.21546938538462,40.372743761538466,41.53001813769231,42.68729251384616,{"y":43.84456689,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >